HK1061797A1 - A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis - Google Patents

A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis

Info

Publication number
HK1061797A1
HK1061797A1 HK04103953.5A HK04103953A HK1061797A1 HK 1061797 A1 HK1061797 A1 HK 1061797A1 HK 04103953 A HK04103953 A HK 04103953A HK 1061797 A1 HK1061797 A1 HK 1061797A1
Authority
HK
Hong Kong
Prior art keywords
osteonecrosis
drug
treatment
patients
risk
Prior art date
Application number
HK04103953.5A
Other languages
English (en)
Inventor
David Graham Little
Nicholas Charles Smith
Original Assignee
Sydney Children S Hospitals Network Randwick And Westmead
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPR2907A external-priority patent/AUPR290701A0/en
Priority claimed from AUPR4187A external-priority patent/AUPR418701A0/en
Priority claimed from AUPR6654A external-priority patent/AUPR665401A0/en
Application filed by Sydney Children S Hospitals Network Randwick And Westmead filed Critical Sydney Children S Hospitals Network Randwick And Westmead
Publication of HK1061797A1 publication Critical patent/HK1061797A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK04103953.5A 2001-02-06 2004-06-02 A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis HK1061797A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AUPR2907A AUPR290701A0 (en) 2001-02-06 2001-02-06 A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis
AUPR4187A AUPR418701A0 (en) 2001-04-03 2001-04-03 A drug for use in bone grafting
AUPR6654A AUPR665401A0 (en) 2001-07-27 2001-07-27 A drug and method for the treatment of osteonecrosis
PCT/AU2001/001616 WO2002062351A1 (en) 2001-02-06 2001-12-13 A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis

Publications (1)

Publication Number Publication Date
HK1061797A1 true HK1061797A1 (en) 2004-10-08

Family

ID=27158265

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04103953.5A HK1061797A1 (en) 2001-02-06 2004-06-02 A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis

Country Status (24)

Country Link
US (2) US7425549B2 (zh)
EP (1) EP1365769B1 (zh)
JP (1) JP2004527479A (zh)
KR (1) KR20030072399A (zh)
CN (1) CN1233325C (zh)
AT (1) ATE496624T1 (zh)
AU (1) AU2002221339B2 (zh)
BR (1) BR0116862A (zh)
CA (1) CA2435552C (zh)
CY (1) CY1111402T1 (zh)
CZ (1) CZ301361B6 (zh)
DE (1) DE60143964D1 (zh)
DK (1) DK1365769T3 (zh)
HK (1) HK1061797A1 (zh)
HU (1) HUP0303013A3 (zh)
IL (1) IL157201A (zh)
MX (1) MXPA03007029A (zh)
NO (1) NO20033446L (zh)
NZ (1) NZ527351A (zh)
PL (1) PL361909A1 (zh)
SI (1) SI1365769T1 (zh)
SK (1) SK9862003A3 (zh)
WO (1) WO2002062351A1 (zh)
ZA (1) ZA200305890B (zh)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60143964D1 (de) * 2001-02-06 2011-03-10 Sydney Children S Hospitals Network Randwick And Westmead Incorporating The Royal Alexandra Hospital Arzneimittel zur behandlung von osteonekrose und zur versorgung von patienten mit risiko für die entstehung von osteonekrose
US20040157798A1 (en) * 2001-04-03 2004-08-12 Little David Graham Drug for use in bone grafting
CA2469779C (en) * 2001-12-21 2008-02-12 The Procter & Gamble Company Method for the treatment of bone disorders
BR0308901A (pt) * 2002-05-10 2005-01-04 Hoffmann La Roche ácidos bisfosfÈnicos para tratamento e prevenção de osteoporose
SI1596870T2 (sl) * 2002-12-20 2011-07-29 Hoffmann La Roche Formulacija z visokim odmerkom ibandronata
ES2275218T3 (es) 2003-05-07 2007-06-01 Osteologix A/S Sales de estroncio hidrosolubles para el tratamiento de afecciones de cartilagos y/o huesos.
WO2005072747A1 (ja) * 2004-02-02 2005-08-11 Ono Pharmaceutical Co., Ltd. 骨吸収抑制剤
ITMI20040218A1 (it) * 2004-02-10 2004-05-10 Abiogen Pharma Spa Uso di neridronato sodico per promuovere la neoformazione ossea
US20080167513A1 (en) 2004-02-26 2008-07-10 Osteologlx A/S Strontium-Containing Compounds for Use in the Prevention or Treatment of Necrotic Bone Conditions
US8012949B2 (en) * 2004-10-08 2011-09-06 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods with enhanced potency for multiple targets including FPPS, GGPPS, and DPPS
US7358361B2 (en) * 2004-10-08 2008-04-15 The Board Of Trustees Of The University Of Illinois Biophosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
WO2006050493A2 (en) * 2004-11-03 2006-05-11 The Regents Of The University Of Michigan Biodegradable implant for intertransverse process fusion
US8071574B2 (en) * 2005-02-22 2011-12-06 John Dennis Bobyn Implant improving local bone formation
CA2646334A1 (en) * 2006-03-17 2007-09-27 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods
US7833270B2 (en) * 2006-05-05 2010-11-16 Warsaw Orthopedic, Inc Implant depots to deliver growth factors to treat osteoporotic bone
US8062364B1 (en) 2007-04-27 2011-11-22 Knee Creations, Llc Osteoarthritis treatment and device
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
CA2769633C (en) 2009-07-31 2017-06-06 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
GB201200868D0 (en) 2012-01-19 2012-02-29 Depuy Int Ltd Bone filler composition
WO2015200032A1 (en) 2014-06-25 2015-12-30 Spine Wave, Inc. Minimally invasive posterolateral fusion
CN105012995B (zh) * 2015-06-04 2018-03-09 武汉维斯第医用科技股份有限公司 一种含促骨愈合药物的胶原蛋白海绵及其制备方法
US9775723B2 (en) 2015-06-16 2017-10-03 Spine Wave, Inc. Instrument and system for placing graft, implant and graft material for minimally invasive posterolateral fusion
AU2017207449A1 (en) * 2016-01-14 2018-08-09 The Regents Of The University Of California Methods of treating osteonecrosis with LLP2A-bisphosphonate compounds
US10195218B2 (en) 2016-05-31 2019-02-05 Grunenthal Gmbh Crystallization method and bioavailability
AU2017204355B2 (en) 2016-07-08 2021-09-09 Mako Surgical Corp. Scaffold for alloprosthetic composite implant

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2151240A1 (en) * 1992-12-23 1994-07-07 Donna T. Whiteford Biophosphonate/estrogen therapy for treating and preventing bone loss
US5403829A (en) * 1993-03-24 1995-04-04 Leiras Oy Use of bisphosphonates in endo-osteal bone surgery
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
US5476865A (en) * 1994-07-06 1995-12-19 Eli Lilly And Company Methods of inhibiting bone loss
CN1113440A (zh) 1994-07-29 1995-12-20 孟照强 一种治疗骨伤的中药制剂及其制备方法
WO1996039974A1 (en) * 1995-06-07 1996-12-19 Implex Corporation Femoral head core channel filling prosthesis
US7041641B2 (en) * 1997-03-20 2006-05-09 Stryker Corporation Osteogenic devices and methods of use thereof for repair of endochondral bone and osteochondral defects
US5843678A (en) * 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
US6316408B1 (en) * 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
EP1027076A2 (de) 1997-10-29 2000-08-16 University Of Pittsburgh Of The Commonwealth System Of Higher Education Verwendung von vektoren wie adenoviren und/oder adeno-assoziierten viren und/oder retroviren und/oder herpes-simplex-viren und/oder liposomen und/oder plasmiden als vehikel für genetische information zur befähigung von säugetierzellen mittel, zur behandlung von knochenpathologien zu produzieren
US6268367B1 (en) * 1998-02-23 2001-07-31 Zymogenetics, Inc. Piperazine derivatives for treating bone deficit conditions
CA2346031A1 (en) 1998-10-15 2000-04-20 Merck & Co., Inc. Methods for stimulating bone formation
KR100763064B1 (ko) * 1999-05-21 2007-10-04 노파르티스 아게 제약 조성물 및 용도
AUPQ232599A0 (en) 1999-08-19 1999-09-09 Royal Alexandra Hospital For Children, The Drug for treating fractures
AU781068B2 (en) * 1999-08-19 2005-05-05 Sydney Children's Hospitals Network (Randwick and Westmead) (incorporating The Royal Alexandra Hospital for Children), The Drug for treating fractures
US6482411B1 (en) * 1999-08-27 2002-11-19 Board Of Regents, The University Of Texas System Methods of reducing bone loss with CD40 ligand
GB0029111D0 (en) 2000-11-29 2001-01-10 Novartis Ag Organic compounds
DE60143964D1 (de) * 2001-02-06 2011-03-10 Sydney Children S Hospitals Network Randwick And Westmead Incorporating The Royal Alexandra Hospital Arzneimittel zur behandlung von osteonekrose und zur versorgung von patienten mit risiko für die entstehung von osteonekrose
AUPR553701A0 (en) 2001-06-07 2001-07-12 Royal Alexandra Hospital For Children, The A device for the delivery of a drug to a fractured bone

Also Published As

Publication number Publication date
HUP0303013A2 (hu) 2003-12-29
CA2435552C (en) 2010-04-27
KR20030072399A (ko) 2003-09-13
US20040097469A1 (en) 2004-05-20
DE60143964D1 (de) 2011-03-10
US7612050B2 (en) 2009-11-03
EP1365769A4 (en) 2005-08-10
CA2435552A1 (en) 2002-08-15
EP1365769A1 (en) 2003-12-03
EP1365769B1 (en) 2011-01-26
ZA200305890B (en) 2005-01-26
US20090005347A1 (en) 2009-01-01
JP2004527479A (ja) 2004-09-09
NZ527351A (en) 2005-01-28
HUP0303013A3 (en) 2007-06-28
US7425549B2 (en) 2008-09-16
CN1233325C (zh) 2005-12-28
MXPA03007029A (es) 2004-10-15
BR0116862A (pt) 2004-01-13
SI1365769T1 (sl) 2011-06-30
NO20033446L (no) 2003-10-01
WO2002062351A1 (en) 2002-08-15
NO20033446D0 (no) 2003-08-04
CZ301361B6 (cs) 2010-01-27
SK9862003A3 (en) 2004-02-03
CZ20032408A3 (cs) 2004-06-16
AU2002221339B2 (en) 2006-04-27
CY1111402T1 (el) 2015-08-05
DK1365769T3 (da) 2011-05-16
CN1529604A (zh) 2004-09-15
ATE496624T1 (de) 2011-02-15
IL157201A (en) 2010-04-29
PL361909A1 (en) 2004-10-04

Similar Documents

Publication Publication Date Title
HK1061797A1 (en) A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis
NO20101190L (no) Anvendelse av buprenorfin i fremstillingen av et medikament
YU25295A (sh) Primena alendronata u proizvodnji leka za sprečavanja periproteznog gubitka kosti kod pacijenata sa ortopedskim implantiranim sredstvima
MXPA03009356A (es) Recipiente esteril para aplicaciones medicas.
AU2003297621A1 (en) Medical devices for delivery of therapeutic agents
YU37602A (sh) Derivat pirolidinacetamida sam ili u kombinaciji za tretman poremećaja cns
AU7031500A (en) Therapeutic quinazoline compounds
EP1139746A4 (en) CONNECTIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY DISEASES AND THE ADMINISTRATION OF MEDICINAL SUBSTANCES
UA86802C2 (ru) Комбинация симетикона и бисакодила для предрасположенных к запору пациентов, которые страдают от ощущения вздутия живота
DK0998287T3 (da) Anvendelse af levobupivacain
HK1080733A1 (en) Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol
GB0020504D0 (en) Therapeutic method
MD970254A (en) Use of melatonine for treatment of patients having a medicamental dependence
AU2003246592A1 (en) Tumour marker and the use thereof for the diagnosis and treatment of tumour diseases
HK1076034A1 (en) Novel association of an antithrombotic agent with aspirin and use thereof for the manufacture of a medicament for treating atherothrombotic diseases
PT1133295E (pt) Utilizacao da nicergolina no tratamento da espasticidade
AUPR290701A0 (en) A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis
IL162492A (en) Use of alkylphosphocholines for producing a medicament for the preventative treatment of protozoan diseases
AU2003236787A1 (en) Use of alkylphosphocholines for the preventative treatment of protozoan diseases
NO953003L (no) Anvendelse av ifenprodil og diastereoisomerer derav for fremstilling av medisinske preparater
GB0208129D0 (en) Method of treatment
AU2908501A (en) Combination therapy for the treatment of inflammatory and respiratory diseases
ZA983211B (en) Use of mizolastine for preparing medication for the treatment of inflammation
AU2003210386A1 (en) Pharmaceutical composition comprising a bisphosphonate and a cox-2 inhibitor for the treatment of bone diseases
YU40098A (sh) Upotreba olanzapina za dobijanje leka

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20141213